Essentially, whilst the biological and clinical effectiveness of managing hypercholesterolemia with statins or other drugs is now straightforward and proven effective when targeting the right population, the clinical management of patients with CHIP remains unexplored territory to date. To put it simply, will cardiovascular genetics foster a super-bright perspective, especially considering the discovery new triggers of CVD, or is this news simply an over-hyped perspective in the ongoing challenge toward establishing effective CVD prevention? Only time will tell.
File in questo prodotto:
Non ci sono file associati a questo prodotto.